LITS
Lite Strategy, Inc.NASDAQHealthcare$1.12-0.88%ClosedMarket Cap: $41.2M
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.09
P/S
0.00
EV/EBITDA
-2.62
DCF Value
$2.68
FCF Yield
-29.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-68.9%
ROA
-47.9%
ROIC
-14.7%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $0.00 | $-30.8M | $-4.62 |
| Q1 2026 | $0.00 | $-3.6M | $-0.55 |
| Q4 2025 | $0.00 | $-2.7M | $-0.40 |
| FY 2025 | $0.00 | $-15.9M | $-2.39 |
Trading Activity
Insider Trades
View AllFile Justin J.director, officer: CEO, CFO and Secretary
SellThu Feb 12
Schornstein Alexander10 percent owner
SellMon Dec 22
Flynn James Pdirector
BuyMon Dec 22
File Justin J.director, officer: CEO, CFO and Secretary
SellThu Nov 20
Flynn James Pdirector
BuyThu Nov 20
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.10
Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.